Cancer Research ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | | | We're introducing a new programme, Bridge to Academic Leadership, to guide postdocs in their transition to an independent group leader position in cancer research.
The programme will offer postdocs routes to develop their skills, confidence, and networks, so that they are ready to lead a research team. They’ll also have an opportunity to apply for a £25k award to build their research portfolio.
Applicants may be currently funded by us or by another funder and may be based at any UK institution. We are a fully inclusive funder and welcome applications from the full diversity of the research community.
Kind regards,
Iain Foulkes
Executive Director Research & Innovation
CEO Cancer Research Horizons
Cancer Research UK |
| | |
| | |
|
|
|
|
Funding & Research Opportunities |
| Get in touch with our office for confidential advice on eligibility, remit and funding options prior to applying. |
|
| | | | | | | | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
|
| | |
|
|
Are you coming to ASCO and/or EACR? |
| Are you attending the ASCO annual meeting in Chicago and EACR in Rotterdam this June?
If you're presenting a poster or speaking at the ASCO Annual Meeting and/or the EACR 2024 Congress, let us know, and we’ll give you a shout out on our socials. |
| | |
|
|
|
Cancer researchers elected as Fellows of the Academy of Medical Sciences |
| Congratulations to the newly elected Fellows of the Academy of Medical Sciences.
Election to the Academy recognises their remarkable contributions to cancer research and the translation of those developments into benefits for patients and wider society.
Join us in congratulating Axel Behrens (Cancer Research UK Convergence Science Centre), Sergio Quezada (University College London Cancer Institute), Eugenia Piddini (University of Bristol), Dean Fennell (University of Leicester), Ivan Ahel (University of Oxford), Adam Mead (University of Oxford), Mark Cragg (University of Southampton) and Niall Martin (Artios Pharma). |
| | |
|
|
|
| | | | | At our Women of Influence meeting back in March, a standout theme in the discussion on allyship was the energy spent by marginalised groups in academic science on a daily basis to ‘fit in’, that could be spent driving scientific progress.
In the latest addition to our research careers column, Research Programme Manager Marjolein Schaap encourages us to listen to people who don’t look, act or sound like us and create spaces where everyone feels like they can be themselves. | | |
| | | | | | | Join your peers from around the world and submit an abstract to present your research at our Brain Tumour Conference.
Don’t miss the chance to join the conference programme, gain valuable feedback on your work and speak alongside the like of Karen Vousden (The Francis Crick Institute), Juanita Lopez (The Royal Marsden), Bissan Al-Lazikani (MD Anderson Cancer Center), Sriram Venneti (University of Michigan) and more.
The submission deadline is this Friday 24 May.
| | |
|
|---|
|
|
|
|
| | The pressing need for allyship |
| | Ed Roberts, Junior Group Leader at our Scotland Institute has set up the Betty Macgregor Annual Memorial Award Showcase to celebrate women who have made a disproportionate impact in cancer research. In our interview with him, Ed makes the point that while it’s good to promote initiatives, it’s equally important to engage in everyday allyship and listen to other people’s experiences, especially when it’s uncomfortable.
There are great initiatives to recognise and remove barriers for marginalised people within academic science, but inclusivity is an active, ongoing process. In this article we explore with Ed the idea that like with any other experiment, we need to monitor the outcomes to check we are achieving the desired effect.
|
| | |
|
|
|---|
|
|
|
|
|
Accelerating adoption of 3Rs methods – NC3Rs Partnerships and Impact awards |
| NC3Rs new Partnership and Impact awards enable the adoption of 3Rs (Replacement, Reduction and Refinement) approaches into new research settings by supporting partnerships between developers and new users of the model. These awards aim to support researchers in testing and validating the use of 3Rs approaches alongside their current animal models, building confidence and demonstrating the approach is fit for purpose.
As part of our continued collaboration with NC3Rs we are jointly funding additional awards available for grants seeking to achieve a 3Rs impact within cancer research. You can join the NC3Rs launch webinar at 2pm, on 6 June 2024 to learn more about the scheme. |
| | |
|
|
|
| | | | | Co-chaired by Eduardo Vilar-Sanchez (MD Anderson Cancer Center) and Sarah Blagden (University of Oxford), the session on precision prevention at our Cancer Prevention Research Conference in Boston this June is an unmissable one.
Join us to hear from Christina Dieli-Conwright (Harvard Medical School), Sharon Savage (NIH/NCI), Matthias Kloor (Heidelberg University Hospital Institute of Pathology) and Ruth Langley (MRC Clinical Trials Unit/UCL) on cutting-edge interventional studies and potential future approaches to lowering risk and preventing cancer in high-risk populations.
Follow #PrevConf24 on our social channels for more conference updates. | | |
| | | | | | | Recruiting patients to clinical trials is an enormous challenge, taking up to 30% of the drug development timeline. For paediatric and rare cancers, the challenge is even greater. This combined with the low incentive for the pharmaceutical industry to develop drugs for smaller patient populations, means too few drug candidates are moving from academia into the clinic.
Non-profit organisations are crucial to meeting this need, but the high cost of clinical trials makes it difficult for them to fund on their own. That’s why, in the past six months, our Centre for Drug Development began partnerships with the Dutch and Norwegian cancer societies to pool resources, expertise and patients, and bring more treatments to underserved patients. | | |
|
|---|
|
|
|
|
New event in data webinar series: whose data is it anyway? |
| Join us on 5 July for the third session in our webinar series on all things research data to dive into issues of trust in how patient data is used in research. Learn how to overcome challenges and unlock opportunities through effective patient and public involvement and engagement strategies.
As well as hearing from members of the public who have been involved in data-driven research, you’ll also hear lightning talks from data-driven cancer researchers, who are adopting novel methods to involve and engage patients and the public.
Chairing the webinar is Matt Howard-Murray (Cancer Research UK Public Involvement Lead for the Research Data Strategy). Our panel of speakers will include Harriet Unsworth (Cancer Research UK National Biomarker Centre) and use MY data. |
| | |
|
|
|
What did you think of this email? |
|
| | |
|
|
| | Together we are
beating cancer |
| | |
|---|
|
|
|
| | | You are playing a crucial role in helping us beat cancer sooner, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here.
Your details are safe with us. Check out our Privacy Policy.
Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise.
This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. |
|
|
|
